Upcoming competitor to Mylan’s EpiPen has equally sleazy pricing rep
Ars Technica » Scientific Method 2016-10-30
Summary:
Rival Kaleo jacked price of drug that reverses opioid overdose amid epidemic.
Link:
http://arstechnica.com/science/2016/10/upcoming-competitor-to-mylans-epipen-has-equally-sleazy-pricing-rep/From feeds:
Berkeley Law Library -- Reference & Research Services » Ars Technica » Scientific MethodCyberlaw » Ars Technica
Music and Digital Media » Ars Technica